CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China's NMPA
SHANGHAI, June 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. The NDA submission is mainly based on the results of an open-label, multicenter, randomized controlled confirmatory Phase II clinical trial (CT041-ST-01, NCT04581473) conducted in China. The data have been presented in The Lancet and at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
In addition, the company is actively expanding satri-cel application in early-line treatment and perioperative treatment of cancer, including an ongoing Phase Ib registrational trial for pancreatic cancer adjuvant treatment and an ongoing investigator-initiated trial for consolidation treatment following adjuvant therapy in patients with resected G/GEJA.
Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of the CT041-ST-01 clinical trial, said, "Gastric cancer is a malignancy with a substantial global disease burden and significant treatment challenges. For patients with advanced gastric cancer, in particular, existing therapeutic options and their efficacy remain severely limited, resulting in extremely poor survival outcomes. Within the current treatment landscape for gastric cancer, a growing number of patients have experienced failure with immunotherapy and anti-angiogenic therapies. Treatment choices and potential benefits become even more constrained in the third-line setting and beyond. Consequently, there exists a significant unmet clinical need for advanced gastric cancer patients after second-line treatment failure. The confirmatory randomized controlled clinical trial of satri-cel has clearly demonstrated that, compared with existing standard therapies, satri-cel offers significant advantages and clinical value in extending both progression-free survival (PFS) and overall survival (OS). The trial results have garnered widespread international attention and recognition, providing a solid evidentiary foundation for satri-cel's New Drug Application (NDA) submission. We look forward to the approval and market launch of satri-cel, which will offer a new treatment option for the broader population of gastric cancer patients."
Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are delighted to announce that the NDA for our self-developed Claudin18.2-targeted CAR T-cell product satri-cel has been accepted for review by China's NMPA. This marks the world's first CAR T-cell therapy product for solid tumors to reach the NDA stage—a major milestone for the CAR-T field. I extend my sincere gratitude to all clinical investigators, trial coordinators, and patients involved in this program. We are hopeful for its timely approval to provide gastric cancer patients with a new treatment option."
About Satri-cel
Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib registrational trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595).
Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA for the treatment of G/GEJA in September 2020.
About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.
Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.
Contact CARsgenFor more information, please visit https://www.carsgen.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/carsgen-therapeutics-announces-nda-acceptance-of-satri-cel-by-chinas-nmpa-302491169.html
SOURCE CARsgen Therapeutics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
A pioneering doctor remembers India leader Indira Gandhi's final moments
Not much about Sneh Bhargava's life seems ordinary. In 1984, she became the first woman to helm the All India Institute of Medical Sciences (AIIMS) in the capital Delhi - one of the country's top medical institutions - and in its almost 70-year history, remains the only woman to have done so. At 90, Dr Bhargava - one of India's pioneering radiologists - began writing her memoir, The Woman Who Ran AIIMS, which was published earlier this month, and at 95, continues to remain an active member in the medical community. From choosing radiology when it was still emerging in 1940s India to becoming one of its most well-known practitioners, Dr Bhargava's legacy is nothing short of extraordinary. Not unlike her first day on the job as director-to-be of AIIMS, which was nothing short of a trial by fire. It was the morning of 31 October 1984, and a meeting was under way at the hospital to confirm her appointment after India's then prime minister Indira Gandhi had selected her for the role. Dr Bhargava was not part of the meeting, but was in her office reviewing medical cases for the day. She recalls in her memoir hearing a colleague frantically call out to her, asking her to rush to the casualty ward. There, lying on a gurney was the very woman who had selected Dr Bhargava to head the hospital - Indira Gandhi. Her saffron sari was drenched in blood and she had no pulse. "At the time, I didn't focus on it being the prime minister who was lying in front of me," Dr Bhargava told the BBC. "My first thoughts were that we had to help her and also protect her from further harm," she said. Dr Bhargava was worried that a mob would storm the casualty ward, as a large crowd had already begun gathering outside the hospital. News began to trickle out: Gandhi had been shot by two Sikh bodyguards in revenge for Operation Blue Star, the military raid on Amritsar's Golden Temple in June to flush out militants. Gandhi's assassination sparked one of the deadliest riots India has seen, the beginnings of which Dr Bhargava began hearing about as she hastened to shift the prime minister to one of the building's top floors. There, in the operating theatre, a Sikh doctor fled the room the minute he heard how Gandhi had died. The news of her death had to be kept under wraps until her son, Rajiv Gandhi was sworn in as prime minister. "Until then, our job, for the next four hours, was to keep up the charade that we were trying to save her life, when in fact she was dead when she was brought to AIIMS," Dr Bhargava writes. She also described the harrowing process of embalming the prime minister's body, which would lie in state in the capital for two days before cremation. "The embalming chemical, when we injected it into different main arteries, kept oozing out," Dr Bhargava writes. A ballistic report would later reveal that over three dozen bullets had punctured Gandhi's body. But this wasn't the only remarkable episode in Dr Bhargava's long and illustrious career at AIIMS. In the book she shares fascinating anecdotes of her interactions with other prominent politicians, including India's first prime minister, Jawaharlal Nehru. She also recalls Sonia Gandhi bringing her son, a young Rahul to AIIMS after an arrow grazed his head while he was playing. "Sonia Gandhi told me that she had to bring Rahul to us because Rajiv (her husband) was meeting the King of Jordan and the latter had given him a fancy car as a gift, which her husband was keen to drive," she writes in the book. Rajiv Gandhi wanted to drive Rahul to AIIMS himself, without security, as a surprise - but Dr Bhargava firmly stopped him, citing safety concerns. But not every day was as exciting. Dr Bhargava recalls political pressure, including an MP who threatened her for not selecting his son-in-law for a job at AIIMS. On another occasion, two top politicians, including the federal health secretary, tried to handpick the AIIMS dean - though the decision was hers alone. Dr Bhargava says she stood firm against pressure, always prioritising patient care. She worked to establish radiology as a core part of diagnosis and treatment at AIIMS. When Dr Bhargava joined in the 1960s, AIIMS had only basic imaging tools. She trained colleagues to read subtle signs in black-and-white X-rays, always in context with the patient's history. She later pushed for better equipment, helping build one of India's leading radiology departments. Dr Bhargava was always drawn to making a difference. Born in 1930 into an affluent family in Lahore in undivided India, as a child she loved playing doctor to her dolls and siblings. During the partition of India and Pakistan, Dr Bhargava's family fled to India and later, she would visit refugee camps with her father to help people. At a time when few Indian women pursued higher education, Dr Bhargava studied radiology in London - the only woman in both her class and hospital department. She returned to India in the 1950s after hearing from her mentor that the country was in need of skilled radiologists. Dr Bhargava often credits her family, and her husband's liberal-mindedness for helping her achieve her dreams, and she hopes other Indian women find the same support. "It starts from childhood," she says. "Parents should support their daughters the same way they support their sons. Only then will they be able to break glass ceilings and reach for the stars." Follow BBC News India on Instagram, YouTube, X and Facebook.
Yahoo
25 minutes ago
- Yahoo
Nike stock price: Why shares are rising despite the shoe giant's revenue decline and serious tariff warning
Shares in Nike, Inc. (NYSE: NKE) are trading much higher this morning after the company announced its Q4 2025 results. Yet those results saw Nike post some of its worst earnings in a while, along with a warning that President Trump's tariffs would cost the company $1 billion in the near term. He was buried in a mushroom casket. Soon he'll be part of the soil CEO of an $11 billion builder empire warns that these housing markets face a short-term oversupply Lifting the veil on the critical—and oft-times overlooked—factors driving AI growth Here's what you need to know about Nike's latest earnings and why the stock is up. Yesterday, the iconic shoemaker announced its Q4 2025 and full-year fiscal 2025 earnings. The results weren't great. For fiscal 2025, Nike reported full-year revenues of $46.3 billion—a 10% decline from fiscal 2024. The company's Q4 2025 revenues totaled $11.1 billion—down 12% from the same quarter a year earlier. The company also posted an earnings per share of 14 cents for its Q4. That EPS was down significantly from the 99 cents the company posted in the same quarter a year earlier. However, perhaps most alarming was the fact that Nike confirmed it would take a $1 billion hit in its current 2026 fiscal year due to the tariffs imposed by President Trump on countries worldwide. The two countries where Nike makes a significant amount of its goods are China and Vietnam. Earlier this year, Trump placed a 46% tariff on goods manufactured in Vietnam and a triple-digit rate on goods made in China. He later reduced both rates, temporarily, to 10% and 30% respectively. Still, Nike chief financial officer Matt Friend said on Nike's earnings call that the tariffs currently in place will result in a 'new and meaningful' cost to Nike, notes CNBC, adding that the company estimates that 'a gross incremental cost increase to Nike of approximately $1 billion.' You would think that Nike's warning of up to $1 billion in tariff-related costs and its pretty dismal Q4 results would send the stock down, not up. But NKE stock is currently up, and significantly, as of the time of the writing. In premarket trading, NKE shares are currently up over 10% to $68.85. There are a few likely reasons for this. First is that, while Nike's Q4 wasn't anything to write home about, the company actually came in above most Wall Street estimates. Analysts had expected Nike to have a pretty poor quarter already, and indeed, as noted by CNBC, Nike had previously said its Q4 would be the low point of its turnaround. This turnaround involves Nike's pivot to return its focus to athletes and shift away from its recent history of trying to cater to the wider 'lifestyle' segment of the population. The turnaround was initiated after Nike brought in a new CEO, Elliott Hill, last October. For its Q4, analysts had been expecting revenue of $10.72 billion and an EPS of 13 cents. So though Nike's Q4 results were disappointing, especially compared to earlier quarters, its actual revenue of $11.1 billion and adjusted EPS of 14 cents came in above expectations—something investors typically reward. But another reason the stock is likely rising in premarket trading is also related to that $1 billion hit Nike is expecting. Though the company says it expects the 10-figure hit this financial year, CFO Matt Friend also said Nike expects to 'fully mitigate' Trump's tariff costs over time. Nike will mitigate these tariff costs by using a three-pronged approach: adjusting its supply chain sources getting its suppliers to absorb some of the costs raising prices on U.S consumers later this year Despite Nike's 10% price surge this morning, shares in the company are still down significantly for the year. As of yesterday's close, Nike shares were sitting at $62.54—down more than 17% for the year. However, that was still significantly above its April lows of nearly $52 per share after President Trump unleashed his 'Liberation Day' tariffs on the world. Over the past 12 months, Nike's shares were down more than 33% as of yesterday's close. This post originally appeared at to get the Fast Company newsletter: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Beijing confirms that it has signed a trade agreement with the US
The US and China have now signed a trade agreement, said China's Ministry of Commerce on Friday, bringing the two economies further into alignment after the threat of a major trade war. A released statement said that China would continue to approve export permits of controlled items, and that the US would "cancel a series of restrictive measures taken against China accordingly". The statement comes after US President Donald Trump told reporters at the White House late on Thursday that the two nations had reached an agreement. 'We just signed with China yesterday,' he said, offering no further details. Initial talks in Geneva in early May led both China and the US to postpone massive tariff hikes that were threatening to freeze much of the trade between the two countries. Later talks in London set a framework for negotiations, and the deal mentioned by Trump appeared to formalise that agreement. China announced earlier this week that it was speeding up export approvals of rare earths, materials used in high-tech products such as electric vehicles. Beijing's limits on exports of rare earths have been a key point of contention. The Chinese Commerce Ministry said on Thursday that Beijing was accelerating a review of export license applications for rare earths and had approved "a certain number of compliant applications." Related Trump says US has reached a trade deal with China US Steel buyout gives Trump a new power: What about future presidents? Export controls of the minerals apparently eclipsed tariffs in the latest round of trade negotiations between Beijing and Washington after China imposed permitting requirements on seven rare earth elements in April, threatening to disrupt production of cars, robots, wind turbines and other high-tech products in the US and around the world. The agreement struck in May in Geneva called for both sides to scale back punitive tariff hikes imposed as Trump escalated his trade war and sharply raised import duties. Some higher tariffs, such as those imposed by Washington related to the trade in fentanyl, as well as duties on aluminium and steel, remain in place. The rapidly shifting policies are taking a toll on both of the world's two largest economies. The US economy contracted at a 0.5% annual pace from January through March, partly because imports surged as companies and households rushed to buy foreign goods before Trump could impose tariffs on them. In China, factory profits sank more than 9% from a year earlier in May, with automakers suffering a large share of that drop. They fell more than 1% year-on-year in January to May. Trump and other US officials have indicated they expect to reach trade deals with many other countries, including India. "We're going to have deal after deal after deal," Lutnick said.
